Outlook Therapeutics


Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.

Industries

Employees

11-50

Links


Org chart

Jennifer Kissner
Executive Vice President, Medical, Clinical, & Regulatory Affairs
Surendra Sharma
Senior Vice President, Medical Affairs
Dan Courtney
Consultant
Glen Olsheim
Executive Director, Commercial Excellence

Board & advisors